High-Throughput Screening Assays for Dengue Antiviral Drug Development.
Methods Mol Biol
; 2296: 279-302, 2021.
Article
em En
| MEDLINE
| ID: mdl-33977455
ABSTRACT
Dengue is an arthropod-borne viral disease that has become endemic and a global threat in over 100 countries. The increase in prevalence would require a long-term measure to control outbreaks. Sanofi Pasteur has licensed the tetravalent dengue vaccine (Dengvaxia) in certain dengue endemic countries. However, the efficacy of the vaccine is limited against certain dengue serotypes and can only be used for individuals from the age from 9 to 45 years old. Over the years, there has been intense research conducted on the development of antivirals against dengue virus (DENV) through either inhibiting the virus replication or targeting the host cell mechanism to block the virus entry. However, no approved antiviral drug against dengue is yet available. In this chapter, we describe the dengue antiviral development workflow including (i) prophylactic, (ii) virucidal, and (iii) postinfection assays that are employed in the antiviral drug screening process against DENV. Further, we demonstrate different methods that can be used to enumerate the reduction in virus foci number including foci-forming unit reduction assay (FFURA), estimation of viral RNA copy number through quantitative real-time PCR, and a high-throughput enzyme linked immunosorbent assay (ELISA)-based quantification of virus particles.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Avaliação Pré-Clínica de Medicamentos
/
Ensaios de Triagem em Larga Escala
/
Desenvolvimento de Medicamentos
Tipo de estudo:
Diagnostic_studies
/
Risk_factors_studies
/
Screening_studies
Idioma:
En
Revista:
Methods Mol Biol
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Malásia